- Home
- RGT vs ALXO Comparison
RGT vs ALXO Comparison
Compare RGT & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGT
- ALXO
- Stock Information
- Founded
- RGT 1986
- ALXO 2015
- Country
- RGT United States
- ALXO United States
- Employees
- RGT N/A
- ALXO N/A
- Industry
- RGT Trusts Except Educational Religious and Charitable
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- RGT Finance
- ALXO Health Care
- Exchange
- RGT Nasdaq
- ALXO Nasdaq
- Market Cap
- RGT 76.6M
- ALXO 76.5M
- IPO Year
- RGT N/A
- ALXO 2020
- Fundamental
- Price
- RGT $11.11
- ALXO $1.89
- Analyst Decision
- RGT
- ALXO Strong Buy
- Analyst Count
- RGT 0
- ALXO 5
- Target Price
- RGT N/A
- ALXO $13.25
- AVG Volume (30 Days)
- RGT 22.4K
- ALXO 1.1M
- Earning Date
- RGT 01-01-0001
- ALXO 11-07-2024
- Dividend Yield
- RGT 1.43%
- ALXO N/A
- EPS Growth
- RGT N/A
- ALXO N/A
- EPS
- RGT 0.92
- ALXO N/A
- Revenue
- RGT N/A
- ALXO N/A
- Revenue This Year
- RGT N/A
- ALXO N/A
- Revenue Next Year
- RGT N/A
- ALXO N/A
- P/E Ratio
- RGT $11.42
- ALXO N/A
- Revenue Growth
- RGT N/A
- ALXO N/A
- 52 Week Low
- RGT $7.84
- ALXO $1.19
- 52 Week High
- RGT $11.08
- ALXO $17.83
- Technical
- Relative Strength Index (RSI)
- RGT 32.07
- ALXO 60.32
- Support Level
- RGT $11.08
- ALXO $1.40
- Resistance Level
- RGT $12.07
- ALXO $1.88
- Average True Range (ATR)
- RGT 0.14
- ALXO 0.19
- MACD
- RGT -0.09
- ALXO 0.02
- Stochastic Oscillator
- RGT 2.53
- ALXO 81.15
About RGT Royce Global Value Trust Inc.
Royce Global Value Trust Inc is a diversified closed-end investment company. The fund spreads its investments across diversified sectors such as information technology, consumer discretionary, health care, materials, consumer staples, and energy. Geographically, it has presence in the region of the United Kingdom, Japan, the United States, Canada, France, Hong Kong, and Germany.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.